AzTrials
AzTrials

Skin InflammationNCT06387212

35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin

A study testing 35 kDa hyaluronan fragment HA35 injection in people with Skin Inflammation and Cosmetic Skin, run by Nakhia Impex LLC at 1 site in Mongolia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Skin Inflammation, Cosmetic Skin
What is being tested?
35 kDa hyaluronan fragment HA35 injection
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteMongolia
Study dates
15 Apr 2024to 22 Jun 2024
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Skin problems include but are not limited to dry skin, dark skin, and coarse pores.
  • Chronic skin inflammation, pigmentation, erythema, etc.
  • Cooperate with the experimental requirements and be able to complete the score independently。

Who cannot join

  • Pregnant or lactating women.
  • Suffering from psychological or mental illness.
  • Life is not regular, overeating.
  • Hypersensitive to hyaluronic acid, and has a scar constitution.

Trial locations and contacts

1 site in 1 country.

Mongolia1 site
  • Nahia Impex LLC

    Ulaanbaatar

Other trials in Mongolia

About this study

Official title: 35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Skin Inflammation

To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.

Being tested
35 kDa hyaluronan fragment HA35 injection
Keywords
whitening, pore size, skin dryness, erythema, skin hardness
Medical subject headings
Dermatitis, Erythema

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 35 kDa hyaluronan fragment HA35 injectionDrug

    Also called HA35

    First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).

Study groups in NCT06387212
Study groupRoleWhat they receive
DermaShine PRO negative microneedles instrumentExperimentalNot described
Receives: Drug: 35 kDa hyaluronan fragment HA35 injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. A skin dryness scale

    The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents no skin dryness, while 10 represents the worst degree of skin dryness.

    Measured: 120 minutes and 960 minutes

  2. A fair or smooth skin scale

    The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the worse degree of fair or smooth skin, while 10 represents the best degree of fair or smooth skin.

    Measured: 120 minutes and 960 minutes

  3. A skin pore size scale

    The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of skin pore size, while 10 represents the worst degree of skin pore size.

    Measured: 120 minutes and 960 minutes

  4. A inflammatory skin thick hardness scale

    The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of inflammatory skin thick hardness, while 10 represents the worst degree of inflammatory skin thick hardness.

    Measured: 120 minutes and 960 minutes

  5. An erythema color and area scale

    The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of erythema color and area, while 10 represents the worst degree of erythema color and area scale.

    Measured: 120 minutes and 960 minutes

Secondary outcomes (1)
  1. Self-satisfaction evaluation

    One week after the end of the treatment, a return visit was conducted to collect the overall satisfaction score of the subjects on the skin treatment. Using the questionnaire (0-10 score) to assess this outcome measure. 0 represents the most dissatisfied, while 10 represents the most satisfied.

    Measured: 1 week after the end of the treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Apr 2024
  2. Study start15 Apr 2024
  3. Primary completion12 May 2024
  4. Study completion22 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06387212
Sponsor's protocol ID
HUI0001
Status last verified
Apr 2024
First submitted
15 Apr 2024
Last updated
23 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in